{"name":"AOP Health","slug":"aop-health","ticker":"Private","exchange":"N/A","domain":"aop-health.com","description":"AOP Health is a private pharmaceutical company specializing in rare and orphan diseases. The company focuses on developing innovative treatments for patients with limited options. With a strong pipeline and established products, AOP Health is well-positioned in the rare disease market. Its key products have shown significant promise in addressing unmet medical needs.","hq":"Vienna, Austria","founded":0,"employees":"","ceo":"Gerhard Gollnisch","sector":"Rare / Orphan Disease","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"Private","metrics":{"revenue":450000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"AOP 021 patent cliff ($100M at risk)","drug":"AOP 021","type":"patent_expiry","sentiment":"negative"},{"date":"2028-06-01","label":"AOP 032 patent cliff ($50M at risk)","drug":"AOP 032","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-15","type":"regulatory","headline":"AOP Health Receives FDA Approval for Rare Disease Treatment","summary":"AOP Health announced that the FDA has approved its treatment for a rare genetic disorder, marking a significant milestone for the company.","drugName":"AOP 021","sentiment":"positive"},{"date":"2023-11-10","type":"deal","headline":"AOP Health Partners with Biotech Firm to Develop New Therapies","summary":"AOP Health has entered into a collaboration agreement with a biotech firm to develop novel treatments for rare diseases.","drugName":"","sentiment":"neutral"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxNQWkxYlNtYkljNkc0ekV5aG9YR1gyODljMmpncHZ0YTM2VG9pM0I1ZFptakdLNEowRHVYWks4SERmQUViNHloN2UwVU92dkZ0QkVCOWpZc2R3ZWFOYXBwYlRXWEduS2RTcndDVkNwLUxGM0tVY2FuRzRDVEx5bUFzLXRVT0thbHV3TkRoU0RGS1hsam45UDF2d1VLQ1dKcFRONGNZTmpabEo2QkZDZHluOF85U0ZfQ25rczc0a1U5RmdGMWtockwyQjEtLVpjelh5cFBZMQ?oc=5","date":"2024-10-01","type":"pipeline","source":"businesswire.com","summary":"Cancer Therapy: AOP Health Investigates a New Approach Targeting Cancer Stem Cells - businesswire.com","headline":"Cancer Therapy: AOP Health Investigates a New Approach Targeting Cancer Stem Cells","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxQLUxFeklTSXRGNHktaVVacWFXdlVxelZkVVR1dnhhUllRelJGVG5oQVg4MWJxNE5JSXZsOW5tTkFfMTNxWTdFcDh3X3YzQU94UTdqU0dvbUFhWWo2T0F4Qjdid1otcy1mZFQyWk9GbFp4ai1FQVVHQkpvRDFSTFVsbUpUbE5BZmZCcXVxNkNkS2ZCM2o0enhGUnY1QVRxQdIBowFBVV95cUxPcjdoNnljcV9icDRCd2FONUNNZUNvNk9uZ2UtZml5YUFqM29lbWczNHctajdEc1JrOGFLcU9Cb29ET2Q5ZTB5SFZac25KdURqWjNWQi1nUl9YTnNBTlYzdkR4RVNDUFRvT3BWTnBkdm1KOWJSRHVuUUlJZWVkMjJxSW5zaFR6RFJIYk5RWmV6Z0hfQWtaZEgwS3VoLXkwQ2lfcnFr?oc=5","date":"2017-01-09","type":"deal","source":"Financial News London","summary":"Deal analysis: Elan hands victory to Perrigo after brutal battle - Financial News London","headline":"Deal analysis: Elan hands victory to Perrigo after brutal battle","sentiment":"neutral"}],"patents":[{"drugName":"AOP 032","drugSlug":"generic-name-for-aop-032","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":50000000},{"drugName":"AOP 021","drugSlug":"generic-name-for-aop-021","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":100000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Shire","Biogen","Pfizer"],"therapeuticFocus":["Rare Genetic Disorders","Orphan Diseases"],"financials":null,"yahoo":null}